MODERNA INC (MRNA) is drawing unusual attention today. Our newswire has captured 2 stories on MRNA across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Moderna Inc stock is moving lower today, down 1.4% in early trading, driven by a gap down from the prior close and a mixed backdrop of recent developments. The stock opened at $62.24 after closing at $63.15 the previous session. While the company recently advanced its clinical pipeline with the dosing of the first US participant in a Phase 1 study for a new cancer therapy candidate, the stock has declined 16% over the last eight sessions, trading at $62.86 as of the previous close.
The immediate catalyst for the move appears to be a gap down at the open. The stock traded as low as $61.06 before bouncing slightly to $61.66 in late afternoon trading. This follows a $178 million patent litigation settlement payment from Moderna to Arbutus Biopharma on July 8, which has drawn attention to the company’s legal exposure. Meanwhile, two major banks, Morgan Stanley and RBC Capital, have raised their price targets for Moderna to $39 and $45 respectively, though both maintain neutral or market-aligned ratings. These updates suggest a cautious outlook despite recent clinical progress.
The stock has traded in a wide 52-week range of $22.28 to $85.60, with a current market cap of $32.5 billion. Over the past four months, Moderna has seen $9.5 million in insider sales, with no insider purchases recorded. Retail and institutional options activity has also been skewed toward calls, with $5.3 million in call premiums exchanged in the last 36 hours. Volume so far is 3.5 million shares, or 0.4 times the 3-month average. The stock remains unprofitable, with a trailing 12-month net margin of -143.6% and a beta of 0.94.
Moderna has no upcoming earnings report scheduled. Investors may want to monitor coverage breadth and any further updates on its clinical trials, particularly for mRNA-4200.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest total since 2022, with 38 acquisitions being completed over the same period, marking the sector’s greatest M&A pace in at least seven years. Underneath […]
Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.
MODERNA INC (MRNA) is drawing unusual attention today. Our newswire has captured 2 stories on MRNA across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "Moderna Stock Has Doubled in 2026, But Wall Street Still Isn’t Convinced" (Yahoo Top).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of MRNA coverage reads 56/100 over 2 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on MRNA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier MRNA move explainers: 2026-07-17 · 2026-07-11